NewcelX Ltd

NCEL

Market cap $19.3M

Study published in Stem Cell Reports demonstrat e s that AstroRx ® - a therapy derived from NewcelX's platform - addresses key barriers to remyelination with potential to treat chronic demyelinating diseases including MS

Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (“NewcelX”; Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the submission of a Pre-Investigational New Drug (“Pre-IND”) briefing package to the U.S. Food and Drug Administration (“FDA”) to support the proposed First-In-Human (“FIH”) clinical trial of NCEL-101 in combination with tegoprubart, an investigational immunomodulatory agent being developed by Eledon Pharmaceuticals (“Eledon”; Nasdaq: ELDN).

NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key long-term value driver toward IND-enabling milestones

ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL),– NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the release of an updated corporate presentation that includes the company's strategic collaboration with Eledon Pharmaceuticals (Nasdaq: ELDN) and highlights the advancement of its flagship Type 1 Diabetes program, NCEL-101, as a central pillar of the company's development strategy.

Financing reflects strong investor confidence and supports advancement of lead Type 1 Diabetes program ZURICH, Switzerland, April 01, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage biopharmaceutical company developing stem cell-based therapies for Type 1 Diabetes, today announced that it has entered into securities purchase agreements for a private placement at a purchase price of $2.75 per share, representing a 30% premium to the last closing price of the Company's common shares on March 31, 2026.

Collaboration Integrates Stem-Cell-Derived Islets with Targeted Immune Modulation ZURICH, Switzerland, March 9, 2026 /PRNewswire/ -- NewcelX Ltd. ("NewcelX") (Nasdaq: NCEL), a clinical-stage company advancing stem-cell-derived therapies for Type 1 Diabetes, today announced a collaborative research agreement with Eledon Pharmaceuticals, Inc. ("Eledon") (Nasdaq: ELDN), a clinical-stage immunology company with a focus on transplant medicine.

Publication strengthens scientific positioning as Company progresses strategic discussions related to CVR-linked asset ZURICH, Feb. 12, 2026 /PRNewswire/ -- NewcelX Ltd. ("NewcelX" or the "Company") (Nasdaq: NCEL), a clinical-stage biopharmaceutical company advancing stem-cell-derived therapies for Type 1 Diabetes and advancing innovative therapies for central nervous system (CNS) today announced the publication of a comprehensive peer-reviewed scientific review entitled, "Mazindol Immediate-Release/Sustained-Release (IR/SR): A 50-Year Legacy of Multifaceted Mechanisms and Emerging Therapeutic Potential," in Clinical Drug Investigation, a Springer Nature journal.

Reinforces strategic focus on Type 1 Diabetes cell therapy and highlights expansion of Scientific Advisory Board and leadership team ZURICH, Jan. 29, 2026 /PRNewswire/ -- NewcelX Ltd. (NASDAQ: NCEL) ("NewcelX" or the "Company"), a clinical-stage cell therapy company advancing transformative treatments for chronic metabolic and neurodegenerative diseases, today announced the release of an updated corporate presentation in advance of its participation in several major spring 2026 investor and partnering conferences, including BIO-Europe Spring in Lisbon.

ZURICH, Jan. 12, 2026 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today reported the results of an international collaborative research study investigating advanced biomaterial strategies to support the delivery and function of stem cell–derived islets for the treatment of Type 1 Diabetes.

ZURICH and NESS ZIONA, Israel, Jan. 5, 2026 /PRNewswire/ -- NewcelX Ltd. (NASDAQ: NCEL) ("NewcelX"), a biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Dr. Julien Boisdron, MD, a seasoned diabetes expert with extensive experience in Swiss big pharma leadership to its Scientific Advisory Board ("SAB").